Previous 10 | Next 10 |
ALPHARETTA, Ga., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its third quarter 2023 financial...
2023-10-18 16:12:44 ET Summary Cornerstone Strategic Value Fund's NAV premium has been eroding, causing the stock to drop significantly. CLM fund's advantage lies in the ability to reinvest dividends at NAV, but the shrinking NAV premium makes this less desirable. Investors sh...
2023-10-17 12:25:33 ET Summary It's been a rough year for CEFs. Between skyrocketing interest rates and liquidity tapering by the Fed, many CEF valuations have plunged to near bear market lows. But have CEF investors completely lost their minds in what they should sell and what th...
2023-10-17 07:34:32 ET Summary Closed-end funds are currently trading at historically deep discounts, with the average discount at -9.64% at the end of Q3 2023. Municipal bond funds are experiencing particularly wide discounts, with an average discount of -12.89%. Non-leverage...
- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial Enrollment is On Track with Data Expected in Q3 2024 - ALPHARETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc...
- Continued Progress in the Global Development and Commercialization of XIPERE ® (known as ARCATUS ® in China) - ALPHARETTA, Ga., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of t...
ALPHARETTA, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that Charles A. Deignan, Chief Financ...
2023-09-20 16:04:12 ET Summary Prior to August 31, 2023, my Readers mentioned 37 equities in their comments on my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, these are ReFa/Ro. Ten analyst-target-estimated TOP-NET-GAIN Re/Fa/Ro: PFE, PBR, O, T...
ALPHARETTA, Ga., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., J.D....
2023-09-11 01:26:06 ET Summary Cornerstone Strategic Value Fund is a closed-end fund that aims for long-term capital appreciation through equity securities. CLM's top holdings closely resemble those of the S&P 500, but it underperforms the market and has a higher expense ratio...
News, Short Squeeze, Breakout and More Instantly...
Cornerstone Strategic Value Fund Inc. Company Name:
CLM Stock Symbol:
NYSE Market:
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ...
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - Robust Safety Profile and Encouraging Efficacy Data Reported Utilizing SCS Microinjector ® - ALPHARETTA, Ga., June 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc....
2024-06-10 15:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...